[Featured Stock] Prestige Biopharma Rises for 2 Consecutive Trading Days on Demonstrating Generic Drug Equivalence
[Asia Economy Reporter Hwang Yoon-joo] Prestige BioPharma has been soaring for two consecutive trading days following the announcement of the equivalence proof of 'HD201,' a biosimilar of the breast cancer treatment drug 'Herceptin.'
As of 9:20 AM on the 25th, Prestige BioPharma is trading at 19,400 KRW, up 6.01% compared to the previous trading day.
On the previous day, Prestige BioPharma announced that the equivalence with 'Herceptin' was proven along with the Phase 3 clinical trial results of HD201. Prestige BioPharma stated, "Currently, the product approval review is underway at the European Medicines Agency (EMA), the Canadian Food and Drug Agency, and the Korean Ministry of Food and Drug Safety," adding, "After EMA product approval, we plan to enter the European market first."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
As the launch of the biosimilar becomes more visible, expectations that it will positively impact performance are interpreted as driving the stock price upward.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
